In Situ Cancer Treatment

  • Hasan Karanlik
  • Abdullah IgciEmail author


Lobular carcinoma in situ is a marker for an increased risk of breast cancer and a non-obligate precursor of invasive carcinoma. Morphological variants of pleomorphic LCIS are accepted as more complex lesions and are more likely to be associated with invasive carcinoma. Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. DCIS is the putative precursor of the majority of invasive breast cancers, and its incidence has increased dramatically with mammographic screening. The goal of the management of DCIS is to prevent the development of invasive breast cancer. This chapter focuses on recommendations for workup, primary treatment, risk reduction strategies, and surveillance specific to carcinoma in situ, which represents approximately 20% of all breast cancers diagnosed by mammography.


Lobular carcinoma in situ Ductal carcinoma in situ LCIS DCIS Pleomorphic 


  1. 1.
    O’Neil M, Madan R, Tawfik OW, Thomas PA, Fan F. Lobular carcinoma in situ/atypical lobular hyperplasia on breast needle biopsies: does it warrant surgical excisional biopsy? A study of 27 cases. Ann Diagn Pathol. 2010;14:251–5.CrossRefGoogle Scholar
  2. 2.
    College of American Pathologists. Protocols and guidelines. Available at: Accessed 26 Feb 2018.
  3. 3.
    EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.CrossRefGoogle Scholar
  4. 4.
    Gradishar WJ, Anderson BO, Balassanian R. Breast Cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.CrossRefGoogle Scholar
  5. 5.
    Leidenius M, Salmenkivi K, von Smitten K, Heikkilä P. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol. 2006;94:380–4.CrossRefGoogle Scholar
  6. 6.
    Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007;14:2911–7.CrossRefGoogle Scholar
  7. 7.
    Meijnen P, Oldenburg HS, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007;94:952–6.CrossRefGoogle Scholar
  8. 8.
    Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.CrossRefGoogle Scholar
  9. 9.
    Cody HS 3rd, Van Zee KJ. Point: sentinel lymph node biopsy is indicated for patients with DCIS. J Natl Compr Cancer Netw. 2003;1:199–206.CrossRefGoogle Scholar
  10. 10.
    Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455–61.CrossRefGoogle Scholar
  11. 11.
    Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34:4040–6.CrossRefGoogle Scholar
  12. 12.
    Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154–70.CrossRefGoogle Scholar
  13. 13.
  14. 14.
  15. 15.
    Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group. J Clin Oncol. 2009;27:5319–24.CrossRefGoogle Scholar
  16. 16.
    McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15.CrossRefGoogle Scholar
  17. 17.
    Smith B. When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol. 2015;33(7):686–91.CrossRefGoogle Scholar
  18. 18.
    Lagios MD, Silverstein MJ. Ductal carcinoma in situ: recent history and areas of controversy. Breast J. 2015;21:21–6.CrossRefGoogle Scholar
  19. 19.
    Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.CrossRefGoogle Scholar
  20. 20.
    Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of the EORCT randomized phase III trial 10853. Lancet. 2000;353:528–33.CrossRefGoogle Scholar
  21. 21.
    UK Coordinating Committee on Cancer Research. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003;362:95–102.CrossRefGoogle Scholar
  22. 22.
    Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28:400–18.CrossRefGoogle Scholar
  23. 23.
    Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014;23:546–51.CrossRefGoogle Scholar
  24. 24.
    Forbes F, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387:866–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Surgical OncologyInstitute of Oncology, Istanbul UniversityIstanbulTurkey
  2. 2.General Surgery, Istanbul Medical Faculty, Department of SurgeryIstanbul UniversityIstanbulTurkey

Personalised recommendations